Background: To determ ine the frequency of m ild cognitive im pairm ent (M CI) of Parkinson's disease (PD, PDM CI) and its subtypes am ong non-dem ented PD patients, and to identify the influence of the age and presenting sym ptom on the development of PDMCI. Methods: A total 141 non-demented PD patients underwent a comprehensive neuropsychological assessm ent including attention, language, visuospatial, m em ory and frontal functions. PDM CI was defined by neuropsychological testing and was classified into five subtypes. Patients were divided into two groups (trem or vs. akinetic-rigid type) for presenting sym ptom and three groups according to the age. Neuropsychological perform ance of patients was com pared with norm ative data. Results: Alm ost half (49.6% ) of non-dem ented PD patients had im pairm ent in at least one dom ain and can be considered as having PDM CI. Executive type of PDM CI was the m ost frequent and am nestic, visuospatial, linguistic and attention types followed in the order of frequency. The population of PDM CI was increasing as the age of disease onset was higher. W hereas the frequency of executive and am nestic types of PDM CI was com parable in younger group, executive type was the m ost frequent in older group. The patients with trem or dom inant type perform ed worse on tests, particularly on attention test. 
INTRODUCTION
Mild cognitive impairment (MCI), a transitional state between the cognitive changes of normal aging and early dementia, can be found not only in patients who will develop Alzheimer's disease (AD) or other neurodegenerative disorders later but also in patients with Parkinson's disease (PD). Initial diagnostic criteria for amnestic form of MCI, proposed by Petersen and colleagues, which required the presence of memory complaints and was corroborated by neuropsychological testing (>1.5 standard deviations (SDs) below age-related normative memory scores), in the absence of dementia, were designed mainly for AD. 1 There are several reasons that we can not adopt these criteria for the diagnosis of MCI in PD. Unlike AD, there can exist various subtypes of MCI in PD, but there have been no established classification and criteria for them. Patients with subtypes of MCI other than amnestic type do not complain subjective symptom corresponding to memory impairment in amnestic MCI. Additionally, the subjective symptom, for example, memory impairment in amnestic MCI may not be important for the diagnosis of MCI because the complaint of memory impairment is very prevalent among individuals whose cognition ranges from normal to severely decreased and patients who are severely demented sometimes do not complain memory disturbance. Therefore, in this study, we defined MCI as impaired performance (i.e., 1.5 SDs or more below the mean of the control group) on Different cognitive profiles may exist within PD. In a study of recently diagnosed patients with PD, 11% had a specific frontostriatal type deficit, 8% had a specific temporal lobe type deficit, whereas 18% had cognitive deficits in both domains. 2 In a community-based study of PD patients with longstanding disease, over 50% of the nondemented patients with PD had some form of cognitive impairment: 20% exhibited predominantly memory deficits, 30% a dominant executive impairment, whereas 50% had a global cognitive impairment. 3 The aim of this study was to explore the population of PDMCI and its subtypes among non-demented PD patients and to examine the influence of the age at disease onset and clinical presentation on the development of PDMCI.
MATERIALS AND METHODS

Subjects
The study population comprised 141 consecutive patients 
Neurological examination
A detailed neurological examination was performed in all patients to check the onset of disease, initial dominant symptoms, medication, and response to medication. The 
Neuropsychological assessment
All patients underwent a comprehensive neuropsychological test using Seoul Neuropsychological Screening Battery (SNSB). 4 Five domains were selected and evaluated as following; attention was assessed with forward digit span. 
Demographic and clinical correlates
To examine whether the age and presenting symptom were related to the development of PDMCI, we divided the patients into 3 groups based on the age at examination; younger than 55 years old, between 55-65 and older than 65. We also divided the patients into 2 groups based on clinical presentation; tremor and akinetic-rigid type. The impaired cognition (PDMCI) and normal cognition groups were compared with respect to demographic and clinical characteristics to identify the variables associated with cognitive function in PD. We analyzed the differences between the groups with respect to age, education periods, K-MMSE scores, symptom duration, treatment duration, levodopa dosage, the UPDRS motor scores of symptoms triad, HY staging and depression scores.
Data analysis
We used t-test to compare the demographic and clinical characteristics between impaired cognition and intact 
RESULTS
Demographic and clinical characteristics
PDMCI patients were older and had lower K-MMSE scores than PD patients with normal cognitive function (Table 1 ). There were no differences between the two groups with respect to sex distribution, education periods, treatment duration, levodopa dosage and geriatric depression scale. Neither disease duration nor disease severity as evaluated by the HY rating scale and the UPDRS motor scores influence the development of PDMCI. The average degree of motor disorder for the patients fell within the mild-to-moderate range. 
Frequency and subtypes of PDMCI
Influence of age at disease onset
The population of PDMCI was increasing as the age of disease onset was higher; 27.5% in younger group, 51.8% in middle aged group and 66.7% in older group. The pattern of involvement was somewhat different depending on the age at disease onset ( 
Influence of presenting symptom
The patients with tremor dominant type performed worse on all domains than those with akinetic-rigid type, but attention was the only domain in which the difference between the two groups reached statistical significance (p<0.05)( Table 2) .
DISCUSSION
The present study examined the frequency and clinical spectrum of PDMCI defined by neuropsychological test.
PDMCI, 49.6% among non-demented patients, was fairly common. This high proportion can be attributed to the definition of PDMCI, which includes patients with impairment of at least one domain of neuropsychological tests, regardless of subjective complaints. Another characteristic finding in our study was that the subtypes of PDMCI were diverse; whereas MCI converting to AD is mainly amnestic type, 1 PDMCI has diverse subtypes. Although executive and amnestic types were most common, visuospatial and linguistic types were not uncommon. This finding indicates that neural substrate responsible for cognitive dysfunction in PD is more diverse and the lesion sites are more widespread and multifocal, contributing to the presence of deficits in multiple neuropsychological domains.
Non-demented patients included in this study may not reflect the whole population because we excluded the patients with the education periods less than 3 years who showed a wide spectrum of cognitive state ranging from highly intelligent to illiterate.
Unlike the MCI developing AD later where amnestic type is far most prevalent, 1 frontal type was the most frequent in PDMCI. This finding is consistent with models describing PD-related changes in dorsolateral prefrontal regions participating in "cognitive" basal ganglia-thalamocortical circuits. 5 In this study, the population of PDMCI increased as the age at disease onset was higher, confirming that the age at disease onset was the most important determinant for cognitive impairment even in non-demented PD, that is, a risk factor for PDMCI.
This result was in agreement with previous studies which focused on cognitive decline in non-demented PD as well as PD dementia.
6,7
Age influenced not only the population of PDMCI but also the pattern of PDMCI. Whereas PDMCI was mainly restricted to single domain in the younger group, the involvement of multiple domain of PDMCI was more common in older group, demonstrating that patients beginning PD at later age had more widespread brain damage. Moreover, in younger group, MCI of amnestic type was as common as MCI of frontal executive type, but in older group, MCI of frontal executive type was much more common than amnestic type of MCI, indicating that frontal dysfunction is more vulnerable in elderly patients with PD. The reason for that is an older individual is more vulnerable to the loss of dopamine (DA) than a young one in PD because a reserve of DA capacity is small in an older individual. 8, 9 And it is generally assumed that, among the 5 domains, frontal executive dysfunction is most closely related to DA loss, explaining it is most frequently involved in PD, particularly in elderly patients.
Our results indicate that the duration of illness had no association with development of PDMCI. This could be attributed to relatively short periods of disease duration, an average of 4.7 years from the disease onset. Longer periods of follow up study will be needed.
Our study showed that the severity as evaluated by the Certainly, it should be interpreted with caution because a small number of subjects were included in that study.
Third, while the efficacy of rivastigmine was proven in the treatment of PDD, 15 the efficacy of acetylcholinesterase inhibitor on PDMCI needs to be investigated. If the efficacy of acetylcholinesterase inhibitor on PDMCI is proven, it can be justified that patient with PDMCI be encouraged to be treated as early as possible.
